Executive Summary
National Cancer Institute Symptom Management and Health-related Quality of Life Steering Committee
Clinical Trial Planning Meeting

Chemotherapy Induced Peripheral Neuropathy: Developing Novel Trials Informed by Translational Science
March 1, 2017

Meeting Co-chairs: Susan Dorsey, PhD, RN, FAAN and Michelle Janelins, PhD, MPH

Meeting Description
The National Cancer Institute (NCI) Symptom Management and Health-related Quality of Life Steering Committee (SxQoL SC) convened a Clinical Trial Planning Meeting on Chemotherapy Induced Peripheral Neuropathy: Developing Novel Trials Informed by Translational Science on March 1, 2017 in Rockville, MD. The primary goal of the meeting was to develop recommendations for one or more clinical trial(s) in chemotherapy induced peripheral neuropathy (CIPN) with an emphasis on utilizing informative biomarkers that will advance our knowledge of its underlying mechanisms. The meeting also focused on the “Lessons Learned” in conducting CIPN research by clinical and translational researchers and NCI Community Oncology Research Program (NCORP) Investigators. The meeting convened clinical and translational science researchers to identify research that is ready to translate from the bench to bedside. In addition, the meeting attendees included SxQoL SC members, behavioral scientists, biostatisticians, patient advocates, and subject matter experts in the clinical management of CIPN, clinical trial design and NCI staff.

Background: What is CIPN, who is affected by it and how is it currently treated?
An estimated 30 to 40 percent of cancer patients treated with chemotherapy experience symptoms of CIPN. Several important features include:

- The symptoms may vary depending on the inciting agent and may include sensory as well as motor dysfunction.
- The symptoms usually start in the hands and/or feet and spread proximally to affect both lower and upper extremities in a characteristic “glove and stocking” distribution. Patients will report a variety of sensations, including tingling, numbness, shooting pain, burning sensations, sharp, stabbing pain, sensitivity to temperature, or some combination of these sensations.
- CIPN can cause loss of functional abilities, making it difficult to perform normal day-to-day tasks like buttoning a shirt, sorting coins in a purse, or walking.
- CIPN is one of the most common reasons that cancer patients stop their treatment early.

For some people, the symptoms can be mitigated by lowering the dose of chemotherapy or temporarily stopping it, which diminishes the pain within a few weeks. But, for other patients, the symptoms last beyond their chemotherapy for months, years, or even indefinitely. Due to dose reduction or temporary dose cessation, many patients do not report or underreport CIPN symptoms so that they can continue life-saving or life-preserving therapy.

Unfortunately, currently we cannot predict who will suffer from CIPN or to what degree they will be affected. Lacking specific therapies and predictive toxicity biomarker(s) for CIPN, current practice has been to use approaches for similar types of nerve pain as listed below. It is important to note that these therapies have not demonstrated true efficacy for CIPN, and virtually all of the drugs to treat peripheral neuropathy carry side effects of their own.
• physical therapy
• complementary therapies such as massage and acupuncture
• medications that can include steroids, antidepressants, anti-epileptic drugs, and opioids for severe pain

Meeting Highlights

There were a series of scientific CIPN presentations that progressed from preclinical studies and animal models to presentations on recent findings in studies with patients.

• Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration (Rosalind Segal)
• Targeting sphingosine 1-phosphate receptor 1 to block and reverse CIPN - insight from preclinical animal models (Daniela Salvemini)
• Targeting cannabinoid receptors and endogenous analgesic systems to suppress chemotherapy-induced neuropathic pain in preclinical models (Andrea Hohmann)
• Mechanisms of axon degeneration in CIPN and therapeutic approaches in animal models (Ahmet Hoke)
• Genetics of CIPN susceptibility and next steps regarding replication and validation studies of prior GWAS findings (Howard McLeod)
• Effects of exercise on CIPN and the role of the brain in CIPN: Evidence from human studies (Ian Kleckner)

The scientific presentations were followed by a panel comprised of clinical experts that discussed the potential clinical trial opportunities based on the presentations and considered the appropriateness/readiness of the pre-clinical findings for clinical research.

The scientific presentations and clinical panel discussions were followed by two, 2 hour breakout groups focused on either CIPN intervention trials or a CIPN longitudinal study. The breakout groups reported back to the meeting participants and the group discussed possible next steps for conducting critical translational trials in CIPN. The consensus from the group was that research in the form of a large longitudinal study to identify trajectories and mechanisms of CIPN as well as intervention research to identify therapies to prevent CIPN or treat CIPN are needed.

Next Steps

Working groups will be convened following the CTPM to develop clinical trial concepts (interventional approaches) or study designs (longitudinal study).

Three WGs will develop concepts focused on the following interventions:

• Duloxetine to prevent CIPN
• S1PR1-targeted agents as CIPN therapeutics
• Exercise interventions for CIPN
Clinical Trials Planning Meeting on Chemotherapy Induced Peripheral Neuropathy: Developing Novel Trials Informed by Translational Science

March 1, 2017
Shady Grove/NCI in Room TE406

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>8:00-8:15</td>
<td>Introductions and Opening Remarks: Overall Goal of the Meeting and Developing Study Design Proposals</td>
<td>Susan Dorsey and Michelle Janelsins CTPM Co-Chairs Debra Barton and Karen Mustian SxQoL SC Co-Chairs</td>
</tr>
<tr>
<td>8:15-8:45</td>
<td>NCI: Programmatic Overview of CIPN Portfolio</td>
<td>Ann O'Mara DCP/NCI Diane St. Germain DCP/NCI</td>
</tr>
<tr>
<td>8:45-10:00</td>
<td>CIPN Research Ideas Potentially Ready for Clinical Research Studies: Biomarkers/Mechanisms and Interventions</td>
<td>Daniel Salvemini Andra Hohmann Howard McLeod</td>
</tr>
<tr>
<td>8:45-10:00</td>
<td>CIPN Research Ideas Potentially Ready for Clinical Research Studies: Biomarkers/Mechanisms and Interventions</td>
<td>Rosalind Segal Andra Hohmann Howard McLeod</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Break (on your own, cafeteria on Terrace Level)</td>
<td></td>
</tr>
<tr>
<td>10:30-11:45</td>
<td>Clinical Research Panel Discussion of Ideas and Appropriateness for Conduct of NCORP Clinical Research Studies in CIPN</td>
<td>Charles Loprinzi, Ellen Lavoie Smith, Supriya Mohile, Dawn Hershman, Judy Paice and Guido Cavaletti</td>
</tr>
<tr>
<td>11:45-1:00</td>
<td>Lunch (non-working, on your own, cafeteria on Terrace Level)</td>
<td></td>
</tr>
<tr>
<td>1:00-2:30</td>
<td>Concept Development Break-Out Groups Longitudinal Studies Treatment/Intervention Trials</td>
<td>Facilitators: Dorsey, Barton, and NCI Facilitators: Janelsins, Mustian and NCI</td>
</tr>
<tr>
<td>2:30-3:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:00-4:00</td>
<td>Concept Development Break-Out Groups (cont.)</td>
<td></td>
</tr>
<tr>
<td>4:00-4:30</td>
<td>Report-outs from the Break-Out Groups</td>
<td>Susan Dorsey, Michelle Janelsins, Ann O'Mara, Diane St. Germain, Karen Mustian, Debra Barton and Participants</td>
</tr>
<tr>
<td>4:30-5:00</td>
<td>Summary of Proposed Trials/Studies and Next Steps</td>
<td>Susan Dorsey and Michelle Janelsins</td>
</tr>
<tr>
<td>5:00</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
SXQOL STEERING COMMITTEE CLINICAL TRIALS PLANNING MEETING
CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY
Planning Committee

Debra Barton, RN, PhD, AOCN, FAAN (SxQoLSC Co-Chair)
University of Michigan School of Nursing

Suzanne Danhauer, PhD
Wake Forest School of Medicine

Susan Dorsey, PhD, RN, FAAN (CTPM Co-Chair)
University of Maryland Baltimore

Judith Hopkins, MD
Piedmont Hematology Oncology Associates

Michelle Janelsins, PhD, MPH (CTPM Co-Chair)
University of Rochester

Katherine Kelly, PhD, RN
Children’s National Health System

Karen Mustian, PhD, MPH (SxQoLSC Co-Chair)
University of Rochester Medical Center

Ann O’Mara, PhD, RN, MPH
Division of Cancer Prevention, National Cancer Institute

Susan Rossi, PhD, MPH
Coordinating Center for Clinical Trials, National Cancer Institute

Julia Rowland, PhD
Division of Cancer Control and Population Sciences, National Cancer Institute

Diane St. Germain, RN, MS
Division of Cancer Prevention, National Cancer Institute
SxQoL Steering Committee Clinical Trials Planning Meeting in Chemotherapy Induced Peripheral Neuropathy: Developing Novel Trials Informed by Translational Science.
NCI Shady Grove
Rockville, Maryland

March 1, 2017

CTPM Planning Chairs

Susan Dorsey, PhD, RN, FAAN
University of Maryland Baltimore

Michelle Janelsins, PhD, MPH
University of Rochester

SxQoL SC Chairs

Debra Barton, RN, PhD, AOCN, FAAN
University of Michigan School of Nursing

Karen Mustian, PhD, MPH
University of Rochester Medical Center

Participant List

JoAnna Brell, MD
MetroHealth Medical Center

Kathleen Calzone, PhD, RN, AGN-BC, FAAN
Center for Cancer Research
National Cancer Institute

Guido Cavaletti, MD
Università di Milano-Bicocca

Susan M. Czajkowski, PhD
Division of Cancer Control and Population Sciences
National Cancer Institute

Richard Fagerstrom, PhD
Division of Cancer Prevention
National Cancer Institute

Jill Fehrenbacher, PhD
Indiana University School of Medicine-Indianapolis

Leslie Ford, MD
Division of Cancer Prevention
National Cancer Institute

Andrew N. Freedman, PhD
Division of Cancer Control & Population Sciences
National Cancer Institute

Patrick Gavin, RPh
Patient Advocate

Jennifer Gewandter, PhD, MPH
University of Rochester
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Gilchrist, PT, PhD</td>
<td>St. Catherine University</td>
</tr>
<tr>
<td>Marge Good, RN, MPH, OCN</td>
<td>Division of Cancer Prevention National Cancer Institute</td>
</tr>
<tr>
<td>Dawn Hershman, MD, MS, FASCO</td>
<td>Columbia University Medical Center</td>
</tr>
<tr>
<td>Daniel Hertz, PharmD, PhD</td>
<td>University of Michigan</td>
</tr>
<tr>
<td>Elizabeth Hile, PhD, PT</td>
<td>University of Oklahoma Stephenson Cancer Center</td>
</tr>
<tr>
<td>Andrea Hohmann, PhD</td>
<td>Indiana University</td>
</tr>
<tr>
<td>Ahmet Hoke, MD, PhD</td>
<td>Johns Hopkins School of Medicine</td>
</tr>
<tr>
<td>Katherine Kelly, PhD, RN</td>
<td>Children's National Health System</td>
</tr>
<tr>
<td>Ian Kleckner, PhD</td>
<td>University of Rochester Medical Center</td>
</tr>
<tr>
<td>Robert Korycinski</td>
<td>Division of Cancer Prevention National Cancer Institute</td>
</tr>
<tr>
<td>Cecilia Lee, DrPH, RN</td>
<td>Division of Cancer Prevention National Cancer Institute</td>
</tr>
<tr>
<td>Glenn Lesser, MD</td>
<td>Wake Forest Baptist Health</td>
</tr>
<tr>
<td>Charles Loprinzi, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Iman Martin, PhD, MPH, MSc</td>
<td>Division of Cancer Prevention National Cancer Institute</td>
</tr>
<tr>
<td>Worta McCaskill-Stevens, MD</td>
<td>Division of Cancer Prevention National Cancer Institute</td>
</tr>
<tr>
<td>Howard McLeod, PharmD</td>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td>Lori Minasian, MD, FACP</td>
<td>Division of Cancer Prevention National Cancer Institute</td>
</tr>
<tr>
<td>Supriya Mohile, MD, MS</td>
<td>University of Rochester</td>
</tr>
<tr>
<td>Ann O'Mara, PhD, RN, MPH</td>
<td>Division of Cancer Prevention National Cancer Institute</td>
</tr>
<tr>
<td>Mark O'Rourke, MD</td>
<td>Greenville Health System Cancer Institute</td>
</tr>
<tr>
<td>Yvette Ortiz, MS</td>
<td>Emmes Corporation</td>
</tr>
<tr>
<td>Judith Paice, PhD, RN</td>
<td>Northwestern University</td>
</tr>
</tbody>
</table>
Bernard Parker, MD, FACP  
Division of Cancer Prevention  
National Cancer Institute

Deb Pearson, RN, MPH  
Division of Cancer Prevention  
National Cancer Institute

Ray Petryshyn, PhD  
Coordinating Center for Clinical Trials  
National Cancer Institute

Dudith Pierre-Victor, PhD, MPH  
Division of Cancer Prevention  
National Cancer Institute

Laurel Pracht, BS  
Ovarian Cancer Research Fund Alliance

Susan Rossi, PhD, MPH  
Coordinating Center for Clinical Trials  
National Cancer Institute

Julia Rowland, PhD  
Division of Cancer Control and Population Sciences  
National Cancer Institute

Daniela Salvemini, PhD  
Saint Louis University

Rosalind Segal, MD, PhD  
Dana-Farber Cancer Institute  
Harvard Medical School

Nonniekaye Shelburne, CRNP, MS, AOCN  
Division of Cancer Control and Population Sciences  
National Cancer Institute

Ellen Lavoie Smith, PhD  
University of Michigan School of Nursing

Diane St. Germain, RN, MS  
Division of Cancer Prevention  
National Cancer Institute

Nathan Staff, MD, PhD  
Mayo Clinic

Roy Strowd, MD  
Wake Forest School of Medicine

Alexandra Thomas, MD  
Wake Forest Baptist Health

Joseph Unger, PhD  
Fred Hutchinson Cancer Research Center